November 23, 2021
1 min watch
Save
VIDEO: Expert discusses TRAIL1 data from ACR
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video from ACR Convergence 2021, Jeffrey A. Sparks, MD, MMSc, associate physician at Brigham and Women's Hospital, discusses results from the TRAIL1 trial in which pirfenidone did not meet its primary endpoints.
“It is a negative trial but ... it is still a drug we might use despite those results,” Spark said.
Reference:
- Dellaripa PF, et al. Abstract 0760. Presented at: ACR Convergence 2021; November 3-10, 2021 (virtual meeting).
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Sparks reports financial disclosures with AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, Inova Diagnostics, Janssen, Musculoskeletal and Skin Diseases, National Institute of Arthritis, Optum, Pfizer and R. Bruce and Joan M. Mickey Research Scholar Fund.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.